In case of V600 BRAF mutation, it seems effective to use RAF inhibitors; RAS and NF1-mutant melanomas have deregulated MEK signaling pathways that are highly sensitive to MEK kinase inhibitors [11], while overexpression of AKT3 isoforms that affects MEK and mTOR signaling pathways has been observed with: wild-type RAS NF1 and Triple Wild-Type cancers, suggesting effective use of target therapy for MEK and PI3K/AKT/mTOR signaling pathway [11]. This evidence concerns the gene NF1 and cancer.